Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | Director | September 22, 2026 | September 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date September 22, 2026 · Filed September 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 56,884 |
Ending reported balance
After 2026-09-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-22 · Exercise / conversion · Acquired 15,940 · Balance 62,443 Row 2 · 2026-09-22 · Tax withholding · Disposed 5,559 · Balance 56,884 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.30 · Expires 2026-10-26 | Direct | 0 |
Reported balance
After 2026-09-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-22 · Exercise / conversion · Disposed 15,940 · Balance 0 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.26 · Expires 2027-10-26 | Direct | 12,500 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 12,500 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.96 · Expires 2028-10-25 | Direct | 7,592 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 7,592 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.41 · Expires 2029-10-24 | Direct | 8,044 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 8,044 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.92 · Expires 2030-10-29 | Direct | 6,028 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 6,028 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $128.81 · Expires 2031-10-28 | Direct | 2,532 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 2,532 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $73.94 · Expires 2032-10-27 | Direct | 3,460 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 3,460 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.51 · Expires 2033-10-26 | Direct | 3,937 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 3,937 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.37 · Expires 2034-10-24 | Direct | 3,511 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 3,511 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.96 · Expires 2035-10-30 | Direct | 3,777 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 3,777 F1: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 26, 2017 Filed Oct 30, 2017 21:03 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (right to buy) · Derivative | 3,125 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003383 · primarydocument.xml · derivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 Underlying: Common Stock · 3,125 shares Expires 2027-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/26/2018) or the date of Bio-Techne 2018 annual meeting of shareholders. Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 21:03 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 739 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003383 · primarydocument.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,712 Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 20:55 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (right to buy) · Derivative | 3,985 | $0.00 Strike: $101.19 | $0.00 |
DisclosureSEC source: 0000914190-16-000863 · edgar.xml · derivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,985 Underlying: Common Stock · 3,985 shares Expires 2026-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/27/17) or the date of Bio-Techne's 2017 annual meeting of shareholders. Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 20:55 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 914 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-16-000863 · edgar.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,973 Read SEC document |
| September 02, 2016 Filed Sep 6, 2016 20:36 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (right to buy) · Derivative | 2,613 | $0.00 Strike: $65.47 | $0.00 |
DisclosureSEC source: 0000914190-16-000813 · edgar.xml · derivative · entry 14 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,613 shares Expires 2018-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2016 Filed Sep 6, 2016 20:36 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 2,613 | $107.15 | $279,986.61 |
DisclosureSEC source: 0000914190-16-000813 · edgar.xml · nonDerivative · entry 5 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,059 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.00 to $107.38 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2016 Filed Sep 6, 2016 20:36 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 2,613 | $65.47 | $171,073.11 |
DisclosureSEC source: 0000914190-16-000813 · edgar.xml · nonDerivative · entry 4 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,672 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 20:36 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (right to buy) · Derivative | 1,467 | $0.00 Strike: $66.59 | $0.00 |
DisclosureSEC source: 0000914190-16-000813 · edgar.xml · derivative · entry 15 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,467 shares Expires 2017-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 20:36 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (right to buy) · Derivative | 2,387 | $0.00 Strike: $65.47 | $0.00 |
DisclosureSEC source: 0000914190-16-000813 · edgar.xml · derivative · entry 13 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,613 Underlying: Common Stock · 2,387 shares Expires 2018-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 20:36 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 3,854 | $107.18 | $413,052.45 |
DisclosureSEC source: 0000914190-16-000813 · edgar.xml · nonDerivative · entry 3 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,059 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.00 to $107.46 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 20:36 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 1,467 | $66.59 | $97,687.53 |
DisclosureSEC source: 0000914190-16-000813 · edgar.xml · nonDerivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 20:36 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 2,387 | $65.47 | $156,276.89 |
DisclosureSEC source: 0000914190-16-000813 · edgar.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,446 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.